The β-secretase enzyme (BACE)-1 inhibition has been a pharmacological strategy for AD as the cleavage of APP by BACE-1 is the first step in the production of soluble Aβ [149,150,151,152,153,154]. Here, BACE1 is linked to Alzheimer disease.